Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00003831




Registration number
NCT00003831
Ethics application status
Date submitted
1/11/1999
Date registered
27/01/2003
Date last updated
14/07/2016

Titles & IDs
Public title
Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer
Scientific title
Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma
Secondary ID [1] 0 0
CDR0000066988
Secondary ID [2] 0 0
ACOSOG-Z0030
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Surgery - conventional surgery

Experimental: Lymph node sampling - Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.

Active Comparator: Lymph node dissection - Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.


Treatment: Surgery: conventional surgery
Intervention code [1] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival
Timepoint [1] 0 0
Up to 5 years
Secondary outcome [1] 0 0
Disease-free survival
Timepoint [1] 0 0
Up to 5 years

Eligibility
Key inclusion criteria
A patient will be eligible for inclusion in this study only if ALL of the following
criteria apply:

Pre-operative:

1. Patient must be =18 years of age.

2. Patient must have an ECOG/Zubrod performance status of = 3.

3. Patient must have tissue diagnosis of a clinically resectable T1 or T2, N0 or
non-hilar N1, M0 NSCLC (squamous cell carcinoma, large cell carcinoma or
adenocarcinoma including bronchoalveolar carcinoma) established prior to
randomization. NOTE: A patient without a pre-operative tissue diagnosis, but with
clinically suspected NSCLC that fits the above criteria is eligible provided the
tissue diagnosis is confirmed intraoperatively.

4. Patient must have pre-operative imaging procedure, CT scan of the chest and upper
abdomen to include liver and adrenal glands to determine eligibility, within 60 days
of the date of the pulmonary resection.

5. Patient that has not had a mediastinoscopy should have no mediastinal adenopathy on
the CT of the chest defined as no lymph node > 1 cm in the shortest axis.

6. Patient is a candidate for a complete resection of the carcinoma via
pneumonectomy,lobectomy, bilobectomy, or anatomic segmentectomy with or without sleeve
resection,as noted in the surgical plan.

7. Patient, or patient's legally acceptable representative, must provide a signed and
dated Z0030-specific written informed consent prior to registration and any
study-related procedures.

8. If patient is a survivor of a prior cancer, the following criteria are met:

1. Patient has undergone potentially curative therapy for all prior malignancies,

2. No evidence of any prior malignancies for at least 5 years with no evidence of
recurrence (except for effectively treated basal cell or squamous carcinoma of
the skin, carcinoma in-situ of the cervix that has been effectively treated by
surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral
breast treated by surgery alone),

3. Patient is deemed by their treating physician to be at low risk for recurrence
from prior malignancies.

Intra-operative:

1. Patient with right-sided lesions must have at least nodal stations #2R, 4R, 7 and 10 R
examined. If the nodes are found, they must be sampled and proven negative by frozen
section.

2. Patient with left-sided lesions must have at least nodal stations #5, 6, 7 and 10L
examined. If the nodes are found, they must be sampled and proven negative by frozen
section.

3. Any other suspicious mediastinal or hilar nodes must be sampled and proven negative by
frozen section. Levels 2, 4 and 7 need not be re-sampled if they were sampled at a
mediastinoscopy done within 60 days of thehoracotomy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A patient will NOT be eligible for inclusion in this study if ANY of the following criteria
apply:

1. Patient has N2 disease determined at pre-operative mediastinoscopy or on sampling.

2. Patient has T3 or T4 tumor.

3. Patient is having only a wedge resection performed for treatment.

4. Patient has received prior chemotherapy or radiotherapy for this cancer.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/1999
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2011
Sample size
Target
Accrual to date
Final
1023
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Centre - East Melbourne
Recruitment hospital [2] 0 0
St. Vincent's Hospital - Fitzroy
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Dakota
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
United States of America
State/province [24] 0 0
West Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Wisconsin
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Other
Name
Alliance for Clinical Trials in Oncology
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Cancer Institute (NCI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
RATIONALE: Surgical removal of all lymph nodes in the chest may kill cancer cells that have
spread from tumors in the lung. It is not yet known whether complete removal of all lymph
nodes in the chest is more effective than removal of selected lymph nodes in treating
patients who have stage I or stage II non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of complete removal of all
lymph nodes in the chest with that of selected removal of lymph nodes during lung cancer
surgery in treating patients who have stage I or stage II non-small cell lung cancer.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00003831
Trial related presentations / publications
Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006 Aug 10;355(6):570-80. doi: 10.1056/NEJMoa060467. Erratum In: N Engl J Med. 2007 Jan 11;356(2):201-2.
Public notes

Contacts
Principal investigator
Name 0 0
Mark S. Allen, MD
Address 0 0
Mayo Clinic
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00003831